An interventional study of Omega 3 intake, morbid obesity and Placebo Capsules in Morbid Obesity, sponsored by Pontificia Universidade Católica do Rio Grande do Sul. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Pontificia Universidade Católica do Rio Grande do Sul · Not applicable, Interventional, and Prevention
Ingestion of capsules of omega 3 EPA and DHA, with 1.8 g of EPA and 1.2 g DHA for morbidly obese patients, will improve the inflammatory status? C-reactive protein? Weight?
Intake of EPA and DHA for the management of morbid obesity in capsules
922 studies on the registry are indexed under Obesity, Morbid; 172 are open to participants now.
This study's enrollment of 46 is below the median of 60 across 590 interventional studies indexed under Obesity, Morbid.
Browse Obesity, Morbid studies →Pontificia Universidade Católica do Rio Grande do Sul is the lead sponsor of 22 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Placebo Capsules
Dietary Supplement: Placebo Capsules
Omega 3 intake, morbid obesity
Dietary Supplement: Omega 3 intake, morbid obesity
Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
Decrease of inflammatory levels on blood
expected from this study verify inflammatory factors such as adipokines, glucose, c reactive protein, lipid profile, triglycerides, and anthropometric data as visceral fat, weight, BMI, in both groups, control and intervention, to see the action of the capsules of omega 3.patient may withdraw any time from ingestion of capsules, and the same will be provided by the laboratory Vitamed, which is regularized with the supervisory bodies and food security of Brazil
Time frame: 08 weeks
Decrease of weight
The weight will be measured before and after the intake of omega 3.
Time frame: 08 weeks
No study locations are listed for this record.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pontificia Universidade Católica do Rio Grande do Sul